Cargando…
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
BACKGROUND: The androgen receptor (AR) is discussed as a prognostic and/or predictive marker in breast cancer patients. METHODS: AR mRNA expression was analysed by RT-qPCR in breast cancer patients treated in the neoadjuvant TECHNO (n = 118, HER2-positive) and PREPARE trial (n = 321, HER2-positi...
Autores principales: | Witzel, Isabell, Loibl, Sibylle, Wirtz, Ralph, Fasching, Peter A., Denkert, Carsten, Weber, Karsten, Lück, Hans-Joachim, Huober, Jens, Karn, Thomas, Mackelenbergh, Marion von, Marmé, Frederik, Schem, Christian, Stickeler, Elmar, Untch, Michael, Müller, Volkmar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964685/ https://www.ncbi.nlm.nih.gov/pubmed/31728025 http://dx.doi.org/10.1038/s41416-019-0630-3 |
Ejemplares similares
-
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018) -
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020) -
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019) -
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021) -
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)